Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Geavanceerde medische apparatuur & technologie

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 12-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,520 ^USD	+10,95%		+12,59%	-5,59%

10/12	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
04/11	Neuronetics, Inc. rapporteert resultaten derde kwartaal en eerste negen maanden tot 30 september 2025	CI

Andere talen

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference	20/11
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression	12/11
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	04/11
Keith J. Sullivan Intends to Retire as Chief Executive Officer of Neuronetics, Inc. on June 30, 2026	04/11
Keith J. Sullivan Intents to Retire as President of Neuronetics, Inc. on June 30, 2026	04/11
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter 2025	04/11
Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025	04/11
Neuronetics: Q3 Earnings Snapshot	04/11
Neuronetics : STIM Corporate Presentation November 2025	04/11
Neuronetics Q3 revenue misses estimates	04/11
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan	04/11
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	31/10
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence	30/10
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand Neurostar Access and Operational Excellence	30/10
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call	21/10
Neuronetics, Inc.(NasdaqGM:STIM) added to S&P Global BMI Index	22/09
Neuronetics - New York Medicaid to cover TMS services for adults with MDD	17/09
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)	17/09
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/08
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	05/08
Neuronetics: Q2 Earnings Snapshot	05/08
Healthcare firm Neuronetics Q2 revenue beats estimates	05/08
Neuronetics Reports Second Quarter 2025 Financial and Operating Results	05/08
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2025	05/08
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference	04/08

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Geavanceerde medische apparatuur & technologie

Andere talen

Filters